Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
NRNRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ Global Market · Currency in USD
$2.55 ▲ +0.06 (+2.41%)
At close: Oct 26, 4:00 PM ET. Market closed.
$2.59 ▲ +0.04 (+1.66%)
After hours: Oct 26, 7:30 PM ET

Summary

Previous Close
$2.49
Open
$2.48
Day's Range
$2.46 – $2.59
52 Week Range
$1.62 – $5.06
Volume
592,936
Avg. Volume
880,496
Market Cap
$110.40M
Beta (5Y Monthly)
2.07
PE Ratio (TTM)
--
EPS (TTM)
-$0.62
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$2.00

Profile: NRx Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
29
CEO
Jonathan C. Javitt

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.21 · Revenue est. $1.22M
DateEst.Actual
Aug 17, 2026-$0.11-$0.44Miss
May 15, 2026-$0.05-$0.04Beat
Mar 23, 2026-$0.09$0.19Beat
Nov 17, 2025-$0.11-$0.27Miss
Aug 18, 2025-$0.15-$0.98Miss
May 15, 2025-$0.30-$0.34Miss

Analyst view

Consensus price target
$2.00 ▼ -21.6%
Range $2.00 – $2.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on NRXP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.